NCQA Unveils Quality Measures

The National Committee for Quality Assurance (NCQA) has unveiled the first set of quality measures to assess disease management clinical outcomes. When finalized, the 12 measures — covering five chronic disease areas — will allow employers, health plans, consumers, and others to evaluate the performance of disease management organizations.

The proposed measures address asthma, ischemic vascular disease, chronic obstructive pulmonary disorder, diabetes, and heart failure. The measures will examine whether patients are getting the right treatment and procedures in managing their lifestyles and reducing risk. For example, one measure will determine whether patients with ischemic vascular disease are controlling their blood pressure appropriately.

“More than 50 million Americans live with one or more chronic conditions,” says NCQA Vice President L. Gregory Pawlson, MD, MPH. “Disease management can be an effective way of improving the quality of their health and lives. Yet we know far too little about the effectiveness of these programs.” NCQA has long assessed the performance of disease management companies through its accreditation and certification processes.

Career Opportunities

HAP, a subsidiary of Henry Ford Health System, is a nonprofit health plan providing coverage to individuals, companies and organizations. This executive develops strategies to meet membership and revenue targets through products, pricing, market segmentation and advertising.  Aligns business among Business Development, Commercial Sales, Medicare and Public Sector Programs and Product Development. Seeks to enhance and be responsible for business development and expansion through the development of an effective product portfolio, strong interpersonal relationships and service excellence.

Apply via email to or online at

Subscribe to Our Newsletters

Monthly table of contents

Be notified as each issue of Managed Care is available online.

Biweekly newsletter

Recent topics have included:

PTCommunity news

New drug approvals, clinical trials, drug management. Three times per week.